Format

Send to

Choose Destination
Eur Respir J. 2018 Sep 6;52(3). pii: 1801485. doi: 10.1183/13993003.01485-2018. Print 2018 Sep.

Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies.

Author information

1
Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
2
Dept of Medicine, Boston University School of Medicine, Boston, MA, USA.
3
Dept of Medicine, University of Washington, Seattle, WA, USA.
PMID:
30190265
DOI:
10.1183/13993003.01485-2018
[Indexed for MEDLINE]

Conflict of interest statement

Conflict of interest: L. Richeldi reports personal fees from Sanofi-Aventis (consultancy), Roche (member of advisory board), Celgene (consultancy), Nitto (consultancy), Fibrogen (member of advisory board), Promedior (member of advisory board), Bristol Myers Squibb (consultancy), DynaMed (editorial activity), Pliant Therapeutics (consultancy), Prometic (consultancy), Asahi Kasei (consultancy) and Biogen (consultancy), and grants and personal fees from Boehringer Ingelheim (member of Steering Committee), all outside the submitted work. Conflict of interest: K.C. Wilson reports being the American Thoracic Society Chief of Documents and Patient Education; therefore, he may have an intellectual bias in favour of ATS-sponsored documents. Conflict of interest: G. Raghu reports other (consultant for IPF studies) from BI, BMS, Biogen, Bellerophan, Fibrogen, Gilead, Nitto, Promedior, Sanofi and Veracyte, and grants from NIH (for IPF studies), all outside the submitted work.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center